Silicon Kidney — Department of Health and Human Services SBIR Phase II: 300

Description

Project Summary End Stage Renal DiseaseESRDaffects just overpeople in the United States and costs Medicare$billion annuallyIn center thrice weekly hemodialysis is the most commonly performed treatment for ESRDbut it suffers from pooryear survival ratesreduced patient quality of lifeand is costlyIn contrastfrequent hemodialysis has demonstratedyear survival rates similar to kidney transplant and has improved intermediate outcomesEven though frequent hemodialysis yields superior outcomes than in center thriceweekly hemodialysisit is performed by less thanof the ESRD population because it is too costly to perform in center and too complex to perform at homeCurrent home hemodialysis systems require patients and caregivers to perform complicated tasks associated with life threatening riskssuch as self care needle sticksThe superior outcomes but low adoption rate of frequent home hemodialysis creates an opportunity for a simple to use and safe home hemodialysis systemThe long term objective of our project is to create a new home hemodialysis systemthe iHemothat will increase the practice of frequent home hemodialysis and improve End Stage Renal DiseaseESRDoutcomes Project Narrative End Stage Renal DiseaseESRDaffects overpeople in the US and costs Medicare approximatelybillion dollars annuallySilicon Kidney is developing a new dialysis treatment that will improve ESRD patient outcomesincrease patient quality of lifeand significantly reduce Medicareandapos s expenditures on ESRD